Lostar (Losartan)

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lostar (Losartan)

Property Description
Active ingredient Losartan potassium
Form Tablet (Oral administration)
Pharmacological class Angiotensin II Receptor Blocker (ARB)
General purpose Sustained reduction of blood pressure
Origin / Status Synthetic, Prescription-only

Losartan (Lostar): Definition and Pharmacological Class

Lostar is a trade name for the prescription-only medication with the active ingredient Losartan potassium. This synthetic compound is classified as an Angiotensin II Receptor Blocker (ARB), a therapeutic class for managing systemic pressure.

Losartan functions as an antagonist of the Angiotensin II type 1 (AT1) receptor, a mechanism distinct from that of ACE inhibitors. ARBs are a primary category of antihypertensive agents.


Composition and Unique Properties

Losartan is supplied predominantly as a tablet, a solid oral dosage form designed for oral administration. The core component is Losartan potassium. While available as a single-ingredient drug, Losartan is often used in fixed-dose combination products with diuretics like hydrochlorothiazide to provide complementary action.

Losartan is a prodrug that relies on liver metabolism to form its more potent active metabolite, EXP 3174, which sustains the therapeutic AT1 receptor blockade. A differentiating factor for Losartan is its uricosuric properties, meaning the molecule helps increase the excretion of uric acid in the kidneys, a unique benefit not shared by all ARBs.


General Therapeutic Purpose

The fundamental purpose of Losartan is to achieve a systemic and sustained reduction in blood pressure. By blocking the effects of the powerful vasoconstrictor Angiotensin II, the drug promotes vasodilation (vessel widening) and decreases overall peripheral resistance. Maintaining consistent pressure control through this mechanism is a standard of care for long-term cardiovascular health.

Regulatory References

  1. Losartan - StatPearls - NCBI Bookshelf
  2. Losartan: MedlinePlus Drug Information

What side effects are possible with Lostar (Losartan)?

Possible Side Effects and Safety Information

The safety profile for Losartan potassium (Lostar) is based on classifications detailed in official regulatory documents, grouping potential adverse effects by their reported frequency and the physiological system affected.


Frequency-Classified Adverse Reactions

Adverse reactions are classified into tiers based on their incidence in clinical use:

  • Common Reactions (ge 1/100 to <1/10 treated individuals) documented in regulatory sources primarily involve the Nervous System (e.g., dizziness) and Gastrointestinal System (e.g., diarrhea). Other effects include fatigue and hyperkalemia (elevated potassium levels).

  • Uncommon Reactions (ge 1/1,000 to <1/100) span multiple systems, including Cardiovascular (e.g., orthostatic effects or drops in pressure upon standing) and Skin (e.g., rash).

  • Rare Reactions (ge 1/10,000 to <1/1,000) include clinically significant events like angioedema, which involves swelling of the face, throat, or tongue, and hepatitis (liver inflammation).


High-Level Safety Constraints

The official label highlights specific safety considerations for certain patient populations and co-administered agents:

  • Population Specifics: Safety notes exist for individuals with underlying conditions such as Hepatic Impairment and Renal Artery Stenosis, where use may require particular caution.

  • Interaction-Related Risk: Co-administration with potassium-sparing agents is associated with an increased risk of hyperkalemia. Similarly, co-administration with certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) carries a documented risk of renal function deterioration.

Overdose and Emergency Response

Overdose and When to Seek Help

Overexposure to Lostar (Losartan) primarily results in an exaggerated pharmacological effect, leading to profound hypotension (excessively low blood pressure). This major clinical manifestation may be accompanied by tachycardia (rapid heart rate) or, in some cases, bradycardia (slow heart rate).

The risk of developing more severe outcomes, including acute renal failure, is heightened in susceptible populations, such as patients with severe volume depletion or pre-existing severe heart failure.

Immediate medical attention must be sought for any signs of severe overexposure, including collapse, signs of shock, or an inability to be awakened. Treatment is strictly defined as symptomatic and supportive, as regulatory guidance confirms that no specific antidote is known, and the active drug metabolite is not effectively removed by hemodialysis.

Official mandated procedures include instituting supportive care immediately if symptomatic hypotension occurs. Close clinical observation and continuous monitoring of vital signs, especially blood pressure and heart rate, are required due to the prolonged half-life of the active metabolite. Intravenous fluid administration is necessary to help restore plasma volume. Gastric decontamination measures, such as activated charcoal, may be considered if the ingestion occurred recently.

Therapeutic Uses of Lostar (Losartan)

Long-Term Management of Chronic Systemic Pressure

Losartan is generally used for the sustained management of chronic systemic pressure elevation (hypertension) in both adult and pediatric patients. Controlling this pressure may contribute to a lessened risk of serious cardiovascular events. This therapeutic domain addresses the underlying vascular strain, and its primary benefit supports maintenance of blood pressure and contributes to long-term cardiovascular stability.


Targeted Therapeutic Support

The medication may offer supportive benefits for high-risk patients by assisting in managing markers of kidney distress (nephropathy) associated with Type 2 Diabetes and coexisting hypertension. It is also relevant in managing hypertension with structural heart changes like Left Ventricular Hypertrophy, where it may contribute to a lessened risk of stroke. Losartan is applied in addressing conditions where supportive blood pressure management is needed, including situations requiring an alternative to other therapeutic approaches.

Quick Fact: Relief for Chronic Vascular Strain

Regulatory References

  1. DailyMed: LOSARTAN POTASSIUM tablet

Eligibility and Restrictions for Use

The eligibility for Losartan Potassium is strictly defined by government regulatory documents, establishing populations for whom the medicine is prohibited, restricted, or approved.

Eligibility Scope

Category Regulatory Status
Populations for whom use is allowed Adults ge 18 years of age. Pediatric patients ge 6 years of age for hypertension [1.2].
Populations for whom use is not recommended Children lt 6 years of age; patients with severe renal impairment (GFR lt 30 mL/min/1.73 m^2) [3.1], [2.4].
Populations for whom use is contraindicated Pregnancy (second and third trimesters); Severe hepatic impairment; Known hypersensitivity to the drug; Co-administration with aliskiren in patients with diabetes or renal impairment [1.1], [1.3], [1.4].

Resulting Eligibility Structure

Official regulatory statements establish absolute contraindications for Losartan based on pregnancy status and certain conditions like severe hepatic impairment. Use is also formally contraindicated when co-administered with aliskiren in diabetic patients or those with moderate to severe renal impairment. Furthermore, the medicine is not recommended for children under 6 years of age and those who are breastfeeding, as per official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Regulatory Interaction Statements

Losartan's official interaction profile is defined by both pharmacodynamic and pharmacokinetic constraints documented in government regulatory sources.

Interaction-Related Restrictions:

Co-administration with Aliskiren is officially contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment (GFR < 60 mL/min/1.73 m^2), based on the documented risks of dual blockade of the Renin-Angiotensin System (RAAS).

Pharmacodynamic Interactions:

Combining Losartan with potassium-sparing diuretics or potassium supplements increases the documented risk of hyperkalemia (elevated serum potassium). Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including selective COX-2 inhibitors, increases the risk of renal function deterioration and may reduce the blood pressure-lowering effect. Losartan also reduces the renal clearance of Lithium, which can lead to increased serum Lithium concentrations and risk of toxicity.

Pharmacokinetic Interactions:

Losartan metabolism involves CYP2C9 and CYP3A4 enzymes. The CYP2C9 inhibitor Fluconazole is documented to increase Losartan exposure by approximately 70% while reducing the exposure of its active metabolite (EXP 3174). Conversely, inducers like Rifampin may decrease the systemic levels of both the parent drug and the active metabolite. Furthermore, patients with hepatic impairment may experience significantly increased Losartan plasma concentrations.

Mechanism of Action

Receptor Antagonism in the Renin-Angiotensin System (RAS)

Losartan, which is converted to the more active metabolite E-3174, operates within domains that regulate the Renin-Angiotensin System (RAS). It functions as a highly selective and competitive antagonist of the angiotensin II type 1 (AT1) receptor found in vascular smooth muscle, the adrenal gland, and other tissues.

Modulation of Vasoconstriction and Systemic Fluid Balance

The drug's core pathway effect is to inhibit the binding of angiotensin II (Ang:II) to the AT1 receptor. This blockade suppresses the Ang II-mediated intracellular signaling cascade, which normally triggers vasoconstriction and the release of aldosterone. This action results in reduced vascular smooth muscle contraction and alterations in renal sodium and water handling.

Influence on Cellular Signaling

Losartan also engages mechanisms that influence long-term cellular processes. By blocking AT1 receptors, this action modulates Ang II-induced cell growth and extracellular matrix deposition signaling pathways within cardiovascular and renal tissues.

Dosage and Administration Information

Losartan is an oral medication provided as film-coated tablets in 25 mg, 50 mg, and 100 mg strengths. The medication may be administered once daily and can be taken with or without food, with tablets intended to be swallowed whole with water.

For most adults, the usual initial dosage is 50 mg once per day, which may be increased to a maximum of 100 mg once daily. Dose adjustments are typically made after several weeks of therapy, as the full therapeutic effect is generally achieved within three to six weeks.

A lower starting dose of 25 mg once daily is indicated for adults with mild-to-moderate hepatic impairment and for patients who may have intravascular volume depletion (for example, those treated with high-dose diuretics). In pediatric patients aged 6 to 16 years, the usual starting dose for hypertension is 0.7 mg/kg once daily, not exceeding 50 mg. If a dose is missed, the standard procedure is to skip the missed dose and resume the regular schedule without taking two doses to compensate.

Recent Clinical Evidence

Lostar (Losartan): Recent Clinical Evidence

Overview of Findings on Losartan

This section outlines the types of outcomes evaluated in studies concerning Losartan use. Losartan is classified as an Angiotensin II Receptor Blocker (ARB). It is primarily studied for its effect on high blood pressure (hypertension), as well as its use in patients with Type 2 diabetes who have kidney disease (nephropathy).

Research has explored the effect of Losartan use on measures of blood pressure control in various adult populations.


Efficacy and Comparative Trials

Studies have investigated the effects of Losartan in comparison to placebo and other active treatments.

  • A meta-analysis of randomized controlled trials (RCTs) reported differences between the Losartan group and the placebo group, showing an association with lower blood pressure readings.
  • Trials assessed whether Losartan treatment led to changes in blood pressure levels over specific treatment periods.
  • In trials comparing Losartan to other antihypertensive agents, the studies assessed differences in achieving target blood pressure goals and associated cardiovascular outcomes.

Research also examined Losartan's effect on measures of kidney function in patients with Type 2 diabetes.


Safety and Long-term Data

Studies evaluated the effects of taking Losartan as prescribed and examined the safety profile of the agent.

  • Studies in specific patient groups, including those with pre-existing conditions, evaluated the incidence of adverse effects.

Long-term follow-up studies have evaluated the sustained nature of treatment effects and the safety profile over extended periods. Findings have been mixed regarding the sustained maintenance of blood pressure control and kidney protection beyond several years of treatment.

Key Studies & References Losartan - StatPearls (FDA approved indications and mechanism of action)

Frequently Asked Questions (FAQ)

Common questions about Lostar (Losartan) (FAQ)


Q: How long does it usually take for Losartan to start lowering blood pressure?

A: Regulatory documents indicate that blood pressure reduction may begin within the first week of starting Losartan. However, the official product information indicates that the full therapeutic effect needed for sustained control is generally achieved after three to six weeks of consistent daily use.


Q: Can Losartan cause swelling in the ankles or feet?

A: Official regulatory documents report that swelling, known medically as edema, is a documented adverse reaction that has occurred in clinical studies. While it is not one of the most common reported side effects, it is a known possibility listed in the official safety profile.


Q: Is it normal to feel dizzy or lightheaded when first starting Losartan?

A: Official safety information lists dizziness as a common adverse reaction when taking Losartan. Lightheadedness or orthostatic effects (a drop in blood pressure when standing up) are also reported, particularly when initiating the medication or following a dose adjustment.


Q: Can Losartan interact with common pain relievers like ibuprofen or naproxen?

A: Official regulatory information states that Losartan can interact with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include common pain relievers like ibuprofen and naproxen. Combining these medications may reduce the blood pressure-lowering effect of Losartan and may increase the risk of deterioration in kidney function.


Q: Can Losartan cause a persistent dry cough like some other blood pressure medicines?

A: Losartan is an Angiotensin II Receptor Blocker (ARB) and is associated with a lower incidence of a persistent dry cough compared to a related class of blood pressure medications called ACE inhibitors. Cough is not typically listed among the most common adverse reactions for Losartan in regulatory documents.


Q: Are there any common over-the-counter cold medicines that interact with Losartan?

A: Losartan may interact with medications that belong to the NSAID class, which are included in some cold remedies. Additionally, certain ingredients in cold medicines, such as decongestants, can potentially raise blood pressure, which may counteract Losartan's effects. Reviewing the ingredients of cold medicines is part of a patient's due diligence.


Q: Can taking Losartan lower my potassium levels?

A: Losartan's mechanism of action is generally associated with a risk of hyperkalemia, meaning elevated potassium levels in the blood. Therefore, Losartan is not typically expected to cause low potassium levels. Potassium monitoring may be part of the therapeutic plan.


Q: Does Losartan affect kidney function in the long run?

A: Losartan is indicated to protect the kidneys in specific patient populations, such as those with Type 2 diabetes and nephropathy. However, its use in patients with pre-existing kidney issues or when combined with certain drugs (like NSAIDs) may require close monitoring due to the documented risk of renal function changes.


Q: What research supports the use of Losartan for high blood pressure?

A: Official information confirms that the use of Losartan for high blood pressure is supported by clinical trials, including Randomized Controlled Trials (RCTs) and meta-analyses. These studies demonstrate Losartan's efficacy in achieving lower blood pressure readings.


Q: What happens if I miss a dose of Losartan?

A: Regulatory guidance advises that if a dose is missed, it should be skipped entirely. The patient should then resume the regular schedule without taking two doses at the same time to compensate for a missed dose.


Q: How often should I have blood tests while taking Losartan?

A: Because Losartan carries documented risks of changes in potassium levels (hyperkalemia) and potential changes to kidney function, periodic monitoring through blood tests is necessary. The decision regarding the exact frequency and type of blood tests is made by a healthcare professional.


Q: Can Losartan be used to prevent a stroke?

A: Yes, according to the official regulatory indications, Losartan is specifically indicated for use in reducing the risk of stroke in patients who have high blood pressure and left ventricular hypertrophy.


Q: Why do doctors often prescribe Losartan with a diuretic (water pill)?

A: Losartan is frequently supplied in fixed-dose combination products with diuretics, such as hydrochlorothiazide. This combination is used because the diuretic provides a complementary action to Losartan, which helps enhance the overall blood pressure reduction achieved.


Q: What are the signs that Losartan is actually working?

A: The primary measure of Losartan's efficacy is achieving a sustained reduction in blood pressure. This reduction is established over several weeks of consistent use, as the full therapeutic effect is not instantaneous.


Q: Does Losartan help with high blood pressure caused by kidney problems?

A: Losartan is a treatment for high blood pressure in general. Furthermore, official indications include its use in patients with Type 2 diabetes who have kidney disease, suggesting its utility in managing hypertension associated with renal conditions.


Q: Why is Losartan sometimes prescribed for people with diabetes?

A: In patients with Type 2 diabetes who also have hypertension, Losartan is specifically indicated for the treatment of associated kidney disease, known as diabetic nephropathy. This use addresses a specific complication of diabetes.


Q: How is Losartan different from an ACE inhibitor like Lisinopril?

A: Losartan is an Angiotensin II Receptor Blocker (ARB) and works by a mechanism distinct from ACE inhibitors. A key difference noted in regulatory documents is that Losartan is generally associated with a lower incidence of the persistent dry cough that can be triggered by ACE inhibitors.


Q: What should I do if my blood pressure drops too low while on Losartan?

A: The official label warns about the risk of symptomatic hypotension (low blood pressure), especially in certain at-risk patients like those who are volume-depleted. If symptoms of low blood pressure are experienced, healthcare providers recommend seeking guidance, as a change in dosage or therapy may be necessary.


Q: Can Losartan affect my heart rate?

A: Official clinical pharmacology data indicates that while Losartan causes a significant decrease in blood pressure, it typically has no clinically significant effect on the heart rate itself. Heart rate changes are generally not a primary consequence of taking this medication.


Q: Is Losartan commonly prescribed for heart failure?

A: Losartan is indicated for high blood pressure, and it is also used in the management of patients who have high blood pressure along with heart failure with reduced ejection fraction. It is recognized as a therapeutic option in heart failure management guidelines.


Q: Can Losartan make me feel tired or fatigued?

A: Yes, official safety information lists fatigue and general lack of energy or weakness (asthenia) as common adverse reactions that were documented in clinical trials for Losartan.


Q: Is it okay to drive or operate machinery after taking Losartan?

A: Losartan may cause dizziness or sleepiness, particularly when treatment begins or after a dosage increase. Due to the potential for these effects, caution is generally recommended before driving or operating machinery until the patient's individual reaction to the medication is clear.


Q: Can Losartan cause changes in mood or sleep?

A: While common side effects include nervous system effects like dizziness, specific changes to mood or sleep patterns are not typically listed among the common or uncommon adverse reactions in the official safety profile for Losartan.


Q: Why does Losartan need to be taken every day, even if I feel fine?

A: Losartan is intended for the long-term, sustained management of high blood pressure. Consistent daily use is necessary to maintain the therapeutic blockade of the Angiotensin II receptor and achieve continuous blood pressure control, which is often asymptomatic.


Q: Is Losartan a lifelong medication for high blood pressure?

A: The management of chronic conditions like hypertension often involves continuous, long-term therapy. The duration of treatment is determined by a healthcare professional based on the individual's condition and treatment goals.


Q: Does alcohol consumption interfere with Losartan?

A: Yes, official warnings state that alcohol consumption may have additive effects with Losartan in lowering blood pressure. This can increase the risk of side effects such as dizziness, lightheadedness, or fainting.


Q: What are the typical expected benefits of taking Losartan?

A: The expected benefits, according to official indications, are a sustained reduction in blood pressure. In specific patient groups, benefits also include a reduced risk of stroke and protection against the progression of kidney disease in people with Type 2 diabetes.


Q: How does Losartan affect the body's fluid balance?

A: Losartan influences fluid balance by blocking Angiotensin II, which in turn reduces the release of the hormone aldosterone. This action results in alterations to how the kidneys handle sodium and water, thus influencing the systemic fluid balance.


Q: Is it better to take Losartan in the morning or at night?

A: Official instructions indicate that Losartan is prescribed as a once-daily dose and can be taken with or without food. The regulatory documents do not specify that taking the medication in the morning offers a clinical advantage over taking it at night, or vice versa.


Q: How does Losartan work to protect the kidneys in diabetic patients?

A: Losartan provides a protective effect in diabetic kidney disease (nephropathy) by blocking the AT1 receptors in the kidney tissue. This modulation helps suppress Angiotensin II-induced cell growth and changes to the tissue structure within the kidneys.


Q: What happens if I accidentally take two doses of Losartan?

A: Taking more than the prescribed amount is considered an overdose. Regulatory warnings indicate that symptoms of overdose may include extremely low blood pressure (hypotension) and changes in heart rate. Immediate professional medical guidance should be sought in case of an accidental double dose.

How should Lostar (Losartan) be stored and disposed of?

Official Storage Requirements for Losartan

Losartan potassium tablets must be stored at Controlled Room Temperature (CRT), defined as 20 C to 25 C (68 F to 77 F). The product must be kept in the original, tightly closed container and stored away from excess heat, moisture, and direct light.

Storage Condition Tablet Requirement
Temperature Controlled Room Temperature
Protection Away from heat, light, and moisture
Child Safety Keep out of the reach of children

If a Losartan oral suspension is prepared by a pharmacist, it must be refrigerated at 2 C to 8 C (36 F to 46 F) and discarded after four weeks. Unused or expired Losartan must be disposed of according to instructions provided by a healthcare professional or local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lostar (Losartan) found in:

A-Z Index: